Menu
Not yet recruiting NCT05617846

Application of Antiosteoporosis Therapy in Osteolysis

Observational Limb; Fusion Complication

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Anti-osteoporosis therapy.
Who it may be relevant to
Registry conditions: Limb; Fusion, Complication. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Efficacy and Safety of Antiosteoporosis Therapy in Patients After Bone Tumor Resection: a Multicenter, Real-world Prospective Cohort Observational Study

Overview

To report the postoperative complications and limb function of patients with osteolysis after surgery for bone tumors of the extremities who received anti-osteoporosis therapy in Henan Cancer Hospital in the next 10 years.

Detailed description

A total of 100 patients with osteolysis after surgery for bone tumors of the four extremities who received anti-osteoporosis treatment in Henan Cancer Hospital in the next 10 years were reported. The basic information, treatment methods, postoperative complications and limb function of these patients were collected.

Interventions

  • Other Anti-osteoporosis therapy
    Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.

Primary outcome measures

  • Complications [Time frame: Collected from the beginning of treatment to 24 months after treatment.]
  • Limb function [Time frame: Collected from the beginning of treatment to 24 months after treatment.]

Eligibility criteria

Inclusion criteria

  • No age restriction, male or female.
  • A subtype of bone tumor (including benign, malignant, and metastatic cancer) was confirmed in the pathology department of the research institution.
  • Received excision of bone tumor in research institution.

Exclusion criteria

Not applicable.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

China · 1 center
  • Department of Bone and Soft Tissue ,Henan Cancer Hospital — Zhengzhou

Identifiers

NCT: NCT05617846 · ZZUSC-19

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗